219 related articles for article (PubMed ID: 20307616)
41. AM630 is an inverse agonist at the human cannabinoid CB1 receptor.
Landsman RS; Makriyannis A; Deng H; Consroe P; Roeske WR; Yamamura HI
Life Sci; 1998; 62(9):PL109-13. PubMed ID: 9496703
[TBL] [Abstract][Full Text] [Related]
42. Characterization of the neuroprotective effect of the cannabinoid agonist WIN-55212 in an in vitro model of hypoxic-ischemic brain damage in newborn rats.
Fernández-López D; Martínez-Orgado J; Nuñez E; Romero J; Lorenzo P; Moro MA; Lizasoain I
Pediatr Res; 2006 Aug; 60(2):169-73. PubMed ID: 16864698
[TBL] [Abstract][Full Text] [Related]
43. The cannabinoid WIN 55,212-2 prevents neuroendocrine differentiation of LNCaP prostate cancer cells.
Morell C; Bort A; Vara D; Ramos-Torres A; Rodríguez-Henche N; Díaz-Laviada I
Prostate Cancer Prostatic Dis; 2016 Sep; 19(3):248-57. PubMed ID: 27324222
[TBL] [Abstract][Full Text] [Related]
44. Effect of Cannabinoid Receptor Agonists on Isolated Rat Atria.
Maggo S; Ashton JC
J Cardiovasc Pharmacol; 2018 Oct; 72(4):191-194. PubMed ID: 30080756
[TBL] [Abstract][Full Text] [Related]
45. Cannabinoid receptor as a novel target for the treatment of prostate cancer.
Sarfaraz S; Afaq F; Adhami VM; Mukhtar H
Cancer Res; 2005 Mar; 65(5):1635-41. PubMed ID: 15753356
[TBL] [Abstract][Full Text] [Related]
46. Prevention of Alzheimer's disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation.
Ramírez BG; Blázquez C; Gómez del Pulgar T; Guzmán M; de Ceballos ML
J Neurosci; 2005 Feb; 25(8):1904-13. PubMed ID: 15728830
[TBL] [Abstract][Full Text] [Related]
47. The cannabinoid WIN 55,212-2-mediated protection of dentate gyrus granule cells is driven by CB1 receptors and modulated by TRPA1 and Cav 2.2 channels.
Koch M; Kreutz S; Böttger C; Grabiec U; Ghadban C; Korf HW; Dehghani F
Hippocampus; 2011 May; 21(5):554-64. PubMed ID: 20135626
[TBL] [Abstract][Full Text] [Related]
48. Cannabinoids and traumatic stress modulation of contextual fear extinction and GR expression in the amygdala-hippocampal-prefrontal circuit.
Ganon-Elazar E; Akirav I
Psychoneuroendocrinology; 2013 Sep; 38(9):1675-87. PubMed ID: 23433741
[TBL] [Abstract][Full Text] [Related]
49. Cannabinoids in the treatment of cancer.
Alexander A; Smith PF; Rosengren RJ
Cancer Lett; 2009 Nov; 285(1):6-12. PubMed ID: 19442435
[TBL] [Abstract][Full Text] [Related]
50. Induction of apoptosis by cannabinoids in prostate and colon cancer cells is phosphatase dependent.
Sreevalsan S; Joseph S; Jutooru I; Chadalapaka G; Safe SH
Anticancer Res; 2011 Nov; 31(11):3799-807. PubMed ID: 22110202
[TBL] [Abstract][Full Text] [Related]
51. Effect of chronic administration of R-(+)-[2,3-Dihydro-5-methyl-3-[(morpholinyl)methyl]pyrrolo[1,2,3-de]-1,4-benzoxazinyl]-(1-naphthalenyl)methanone mesylate (WIN55,212-2) or delta(9)-tetrahydrocannabinol on cannabinoid receptor adaptation in mice.
Sim-Selley LJ; Martin BR
J Pharmacol Exp Ther; 2002 Oct; 303(1):36-44. PubMed ID: 12235230
[TBL] [Abstract][Full Text] [Related]
52. Evidence for a modulatory role of cannabinoids on the excitatory NANC neurotransmission in mouse colon.
Mulè F; Amato A; Baldassano S; Serio R
Pharmacol Res; 2007 Aug; 56(2):132-9. PubMed ID: 17574859
[TBL] [Abstract][Full Text] [Related]
53. CB1 receptors and post-ischemic brain damage: studies on the toxic and neuroprotective effects of cannabinoids in rat organotypic hippocampal slices.
Landucci E; Scartabelli T; Gerace E; Moroni F; Pellegrini-Giampietro DE
Neuropharmacology; 2011 Mar; 60(4):674-82. PubMed ID: 21130785
[TBL] [Abstract][Full Text] [Related]
54. Inhibitory effects of SR141716A on G-protein activation in rat brain.
Sim-Selley LJ; Brunk LK; Selley DE
Eur J Pharmacol; 2001 Mar; 414(2-3):135-43. PubMed ID: 11239913
[TBL] [Abstract][Full Text] [Related]
55. Cannabinoids Induce Cell Death and Promote P2X7 Receptor Signaling in Retinal Glial Progenitors in Culture.
Freitas HR; Isaac AR; Silva TM; Diniz GOF; Dos Santos Dabdab Y; Bockmann EC; Guimarães MZP; da Costa Calaza K; de Mello FG; Ventura ALM; de Melo Reis RA; França GR
Mol Neurobiol; 2019 Sep; 56(9):6472-6486. PubMed ID: 30838518
[TBL] [Abstract][Full Text] [Related]
56. Investigation of non-CB
Breivogel CS; McPartland JM; Parekh B
J Recept Signal Transduct Res; 2018 Aug; 38(4):316-326. PubMed ID: 30376752
[TBL] [Abstract][Full Text] [Related]
57. The expression level of CB1 and CB2 receptors determines their efficacy at inducing apoptosis in astrocytomas.
Cudaback E; Marrs W; Moeller T; Stella N
PLoS One; 2010 Jan; 5(1):e8702. PubMed ID: 20090845
[TBL] [Abstract][Full Text] [Related]
58. The novel endocannabinoid receptor GPR55 is activated by atypical cannabinoids but does not mediate their vasodilator effects.
Johns DG; Behm DJ; Walker DJ; Ao Z; Shapland EM; Daniels DA; Riddick M; Dowell S; Staton PC; Green P; Shabon U; Bao W; Aiyar N; Yue TL; Brown AJ; Morrison AD; Douglas SA
Br J Pharmacol; 2007 Nov; 152(5):825-31. PubMed ID: 17704827
[TBL] [Abstract][Full Text] [Related]
59. Species differences in cannabinoid receptor 2 (CNR2 gene): identification of novel human and rodent CB2 isoforms, differential tissue expression and regulation by cannabinoid receptor ligands.
Liu QR; Pan CH; Hishimoto A; Li CY; Xi ZX; Llorente-Berzal A; Viveros MP; Ishiguro H; Arinami T; Onaivi ES; Uhl GR
Genes Brain Behav; 2009 Jul; 8(5):519-30. PubMed ID: 19496827
[TBL] [Abstract][Full Text] [Related]
60. Regulation of Fas receptor/Fas-associated protein with death domain apoptotic complex and associated signalling systems by cannabinoid receptors in the mouse brain.
Alvaro-Bartolomé M; Esteban S; García-Gutiérrez MS; Manzanares J; Valverde O; García-Sevilla JA
Br J Pharmacol; 2010 Jun; 160(3):643-56. PubMed ID: 20590568
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
